Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 4/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307659 | 0.91 | TBXAS1 (0.44) | TBXAS1NOS1ADRA2CCYP19A1HMOX1 | |
| SCHEMBL6394302 | 0.85 | ADRA2C (0.44) | TBXAS1NOS1ADRA2CCYP19A1IDO1 | |
| SCHEMBL6305205 | 0.78 | ADRA2C (0.51) | TBXAS1NOS1ADRA2CCYP19A1HMOX1 | |
| SCHEMBL6215482 | 0.76 | KDM4E (0.40) | CYP19A1CYP3A4CYP2C9 | |
| SCHEMBL6312563 | 0.74 | CYP19A1 (0.45) | ADRA2CCYP19A1IDO1 | |
| SCHEMBL6211726 | 0.72 | QPCT (0.45) | TBXAS1NOS1CYP3A4CYP2C9 | |
| SCHEMBL6391012 | 0.72 | ADRA2C (0.60) | TBXAS1NOS1ADRA2CCYP19A1HMOX1 | |
| SCHEMBL6211720 | 0.71 | QPCT (0.40) | TBXAS1 | |
| SCHEMBL6305674 | 0.71 | ADRA2C (0.71) | TBXAS1ADRA2CCYP19A1IDO1CYP3A4 | |
| SCHEMBL31180917 | 0.71 | ADRA2C (0.71) | TBXAS1ADRA2CCYP19A1IDO1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916813-B2 | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040039033-A1 | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039033-A1 | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase | ATP5F1A, ATP5ME, ATP5F1D | TBXAS1 1914/4885NOS1 2532/4885ADRA2C 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.